Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

781 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.
Schoenfeld DA, Moutafi M, Martinez S, Djureinovic D, Merkin RD, Adeniran A, Braun DA, Signoretti S, Choueiri TK, Parisi F, Hurwitz M, Rimm DL, Wei W, Jilaveanu L, Kluger HM. Schoenfeld DA, et al. Among authors: choueiri tk. J Immunother Cancer. 2023 Aug;11(8):e007240. doi: 10.1136/jitc-2023-007240. J Immunother Cancer. 2023. PMID: 37586773 Free PMC article.
Risk of bilateral renal cell cancer.
Wiklund F, Tretli S, Choueiri TK, Signoretti S, Fall K, Adami HO. Wiklund F, et al. Among authors: choueiri tk. J Clin Oncol. 2009 Aug 10;27(23):3737-41. doi: 10.1200/JCO.2008.20.6524. Epub 2009 Jul 13. J Clin Oncol. 2009. PMID: 19597028
BRAF mutations in metanephric adenoma of the kidney.
Choueiri TK, Cheville J, Palescandolo E, Fay AP, Kantoff PW, Atkins MB, McKenney JK, Brown V, Lampron ME, Zhou M, Hirsch MS, Signoretti S. Choueiri TK, et al. Eur Urol. 2012 Nov;62(5):917-22. doi: 10.1016/j.eururo.2012.05.051. Epub 2012 Jun 9. Eur Urol. 2012. PMID: 22727996 Free PMC article.
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
Choueiri TK, Cheng S, Qu AQ, Pastorek J, Atkins MB, Signoretti S. Choueiri TK, et al. Urol Oncol. 2013 Nov;31(8):1788-93. doi: 10.1016/j.urolonc.2012.07.004. Epub 2012 Nov 7. Urol Oncol. 2013. PMID: 23141780 Free PMC article.
Renal-cell carcinoma: a step closer to a new classification.
Choueiri TK, Pomerantz MM, Signoretti S. Choueiri TK, et al. Lancet Oncol. 2013 Feb;14(2):105-7. doi: 10.1016/S1470-2045(12)70599-5. Epub 2013 Jan 16. Lancet Oncol. 2013. PMID: 23333115 No abstract available.
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S. Choueiri TK, et al. Clin Cancer Res. 2013 Sep 15;19(18):5218-26. doi: 10.1158/1078-0432.CCR-13-0491. Epub 2013 Jul 23. Clin Cancer Res. 2013. PMID: 23881929 Free PMC article. Clinical Trial.
781 results